pharmaphorum

SEPTEMBER 15, 2022

The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”

Dermatology 105

Dermatology Production Pharma Companies Marketing 105

pharmaphorum

JANUARY 18, 2022

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. It’s an amazing opportunity to put their knowledge and experience in dermatology, together with our expertise in molecular glues to accelerate drug discovery to treat skin diseases.

Dermatology 52

Dermatology Protein Pharma Companies Research 52

pharmaphorum

JUNE 2, 2021

Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopic dermatitis or eczema. . Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

XTalks

JULY 16, 2021

Related: Google Launches AI-Based Dermatology Assist Tool. In fact, benzene is one of the 20 most widely used chemicals in the US, serving as a starting material for making plastics, dyes, rubbers, drugs and pesticides. Benzene is a colorless flammable liquid that has a sweet odor. Despite this, contamination issues still persist.

Contamination 105

Contamination Production Drugs Branding 105

XTalks

DECEMBER 20, 2023

These advancements and trends addressed important industry challenges and offered opportunities to foster innovations and solutions in areas including drug development, healthcare and medical devices. The shortages have been partly blamed on the off-label prescribing of the drugs for weight loss.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59

XTalks

NOVEMBER 2, 2023

Amgen’s Wezlana (ustekinumab-auub) has received US Food and Drug Administration (FDA) approval as a Stelara biosimilar for the treatment of several inflammatory diseases including Crohn’s disease, ulcerative colitis (UC), plaque psoriasis and psoriatic arthritis. billion in sales, accounting for ten percent of Johnson & Johnson’s revenue.

FDA Approval 59

FDA Approval Production Dermatology Sales 59

pharmaphorum

FEBRUARY 1, 2021

Almirall is a specialist in psoriasis therapies with drugs like Skilarence (dimethyl fumarate) and Ilumetri (tildrakizumab), while Happify’s app is designed to drive away negative thoughts through the use of games, mindfulness exercises and other activities such as carrying out acts of kindness.

Pharma Companies 124

Pharma Companies Development Drugs Dermatology 124